Onxeo S.A. announced that the company’s Chief Scientific Officer, Françoise Bono, will present OX401, a next-generation PARP inhibitor (PARPi) of the company, during an oral presentation at the PARP & DDR Inhibitors Summit 2020 held in Boston, MA on January 29 to 30, 2020. OX401 is the second candidate sourced from Onxeo's proprietary platform of decoy agonists, platON. This new compound was optimized to maintain this unique mechanism of action, while targeting other DNA-binding proteins and other mechanisms involved in tumor growth, such as the immune response. Its properties position OX401 at the crossroads of two of the most active areas in oncology, DNA Damage Response and immunotherapy.